



Burden of Anemia Due to Chronic Kidney Disease

Prevalence of Anemia Due to CKD Increases With Disease Progression¹




Higher Clinical Burden is Demonstrated in Patients With Anemia and CKD (Stages 3-4)



Annual Hospitalization Rate Is Significantly Higher³




Reduced Quality of Life Is Associated With Anemia in Patients With CKD (Stages 3-5D)



Exercise Capacity Is Greatly Reduced^{5,†}



Anemia Is Correlated With Accelerated CKD Progression³




Treatment Landscape of Anemia Due to CKD^{6,7}

The treatment landscape of anemia due to CKD includes iron supplementation, ESAs, hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs), and RBC transfusion, which all improve clinical measures by balancing potential benefits with risks.

ESAs have remained a mainstay for 30 years by increasing Hb levels and decreasing the need for RBC transfusions. HIF-PHIs are the latest addition to the treatment landscape as oral treatments which stimulate endogenous erythropoietin production.

Both ESAs and HIF-PHIs are recommended to be used to maintain Hb levels within 10 to 11 g/dL and have a warning of increased risk of death and cardiovascular events.


This is based on findings from randomized clinical trials that led to changes in regulatory and clinical practice guidance outlined below.



[†]Decision to start ESA for NDD-CKD should be individualized based on rate of Hb concentration decline, prior response to iron therapy, risk of needing transfusion, risk related to ESA therapy, and anemia symptoms.

⁵For DD-CKD, ESA should be initiated to prevent a decline in Hb to <9.0 g/dL.

Mean Hemoglobin Levels in ESA-Treated Hemodialysis Patients¹⁵



Abbreviations List: CKD, chronic kidney disease; CV, cardiovascular; DD, dialysis-dependent; EPO, erythropoietin; ESA, erythropoiesis-stimulating agent; FDA, Food and Drug Administration; Hb, hemoglobin; KDIGO, Kidney Disease Improving Global Outcomes; NDD, non-dialysis-dependent; pts, patients; RBC, red blood cell; USRDS, United States Renal Data System

References: 1. Stauffer ME, Fan T. PLoS One. 2014;9:e84943; 2. Covic A, et al. Adv Ther. 2017;34:1662-1672; 3. Portolés J, et al. BMC Nephrol. 2013;14:2; 4. Eriksson D, et al. BMC Nephrol. 2016;17:97; 5. Odden MC, et al. J Am Soc Nephrol. 2004;15(11):2908-2915; 6. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl. 2012;2:279-335; 7. Haase VH. Kidney Int Suppl (2011). 2021 Apr;11(1):8-25; 8. US Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>. Accessed April 11, 2024; 9. Besarab A, et al. N Engl J Med. 1998;339:584-590; 10. Drüeke TB, et al. N Engl J Med. 2006;355:2071-2084; 11. Singh AK, et al. N Engl J Med. 2006;355:2085-2098; 12. Fishbane S, Nissenson AR. Kidney Int. 2007;72(7):806-813; 13. Pfeffer MA, et al. N Engl J Med. 2009;361:2019-2032; 14. US Food and Drug Administration. FDA Drug Safety Communication: Modified dosing recommendations to improve the safe use of Erythropoiesis-Stimulating Agents (ESAs) in chronic kidney disease. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-modified-dosing-recommendations-improve-safe-use-erythropoiesis>. Accessed April 11, 2024; 15. United States Renal Data System. 2018 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. Volume 2: End-Stage Renal Disease in the United States. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2018: chap. 2.